Pulsenmore Announces Full Year 2025 Earnings Conference Call
Pulsenmore (NASDAQ: PLSM) will release full year 2025 financial results on March 30, 2026 at 8:30 a.m. Eastern Time and will host a conference call and webcast to review results, business highlights, and recent progress.
Rhea-AI Summary
Pulsenmore (NASDAQ: PLSM) will release full year 2025 financial results on March 30, 2026 at 8:30 a.m. Eastern Time and will host a conference call and webcast to review results, business highlights, and recent progress.
Management presenting includes Jonathan Adereth (Chairman), Dr. Elazar Sonnenschein (CEO), Eran Hirsh (CFO), and Mira Altmark-Sofer (VP Marketing). The live webcast link and replay will be available on the company's Investor Relations website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PLSM
On Mar 25, the day this news came out, PLSM closed 5.51% below the previous close.
Data tracked by StockTitan Argus for the Mar 25 session.
Key Figures
- Earnings release date
- March 30, 2026
- Full year 2025 results release and conference call
- Conference call time (ET)
- 8:30 a.m. Eastern Time
- Start time for FY 2025 earnings call
- Conference call time (Israel)
- 3:30 p.m. Israel Time
- Local time for FY 2025 earnings call
- Clalit agreement value
- $4.5 million
- Potential value over five years from Jan 26, 2026 agreement
- Pregnancies managed
- 1,500 pregnancies per year
- Patient volume at CFFM cited in Feb 2, 2026 engagement
- Pilot duration
- 18-month pilot
- Pulsenmore FC pilot period in Clalit agreement
Historical Context
-
New commercial services agreement post-FDA clearance in U.S. prenatal care.
-
First U.S. commercial engagement for home pregnancy ultrasound product.
-
Strategic Clalit agreement to deploy Pulsenmore FC for at-home fertility monitoring.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
OMER,
The Company will host a conference call and webcast to discuss its financial results, business highlights, and recent progress.
Conference Call & Webcast Details
Date: March 30, 2026
Time: 8:30 a.m. Eastern Time/ 3:30 p.m. Israel Time
Webcast: https://teams.microsoft.com/meet/3845461353556?p=fcIpXc4mErwEAqo3Ir
Replay: The meeting will be recorded, and the recording will be made available following the meeting on the Company's Investor Relations website at: https://pulsenmore.com/investor_relations/
Pulsenmore's executive leadership team, including Jonathan Adereth, Chairman of the Board of Directors, Dr. Elazar Sonnenschein, Founder and Chief Executive Officer, Eran Hirsh, Chief Financial Officer, and Mira Altmark-Sofer, Vice President of Marketing, will host the call to review the Company's financial results, key strategic initiatives, and recent operational progress.
About Pulsenmore
Pulsenmore Ltd. is dedicated to revolutionizing maternal health through the development of home-use ultrasound technology that connect mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com
This press release contains forward-looking statements. In particular, statements using words such as "may," "seek," "will," "consider," "likely," "assume," "estimate," "expect," "anticipate," "intend," "believe," "contemplate," "do not believe," "aim," "goal," "due," "predict," "plan," "project," "continue," "potential," "positioned," "guidance," "objective," "outlook," "trends," "future," "could," "would," "should," "target," "on track" or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to Pulsenmore's continued commercial momentum, clinician adoption expansion, strengthening its presence in the U.S. market following its Nasdaq listing and FDA De Novo authorization and executing on its mission to broaden access to remote prenatal care through physician-directed, technology-enabled solutions. Forward-looking statements reflect Pulsenmore's current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company's lack of operating history; the Company's current and future capital requirements and the Company's belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company's ability to manufacture, market and sell its products and to generate revenues; the Company's ability to maintain its relationships with key partners and grow relationships with new partners; the Company's ability to maintain or protect the validity of its
Investor Contact:
Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com
Logo - https://mma.prnewswire.com/media/2942134/Pulsenmore_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/pulsenmore-announces-full-year-2025-earnings-conference-call-302724789.html
SOURCE Pulsenmore Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.